Pharmala Biotech Aktie - MDMA

Pharmala Biotech Holdings Inc (MDMA) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

0,14

( - )

Gebot

0,135

Fragen

0,16

Volumen

22.850

0,135 Tagesbereich 0,145

0,085 52-Wochen-Bereich 0,195

Marktkapitalisierung

15,244M

Handelsende

0,14

Handelsbeginn

0,145

Letzte Trade

7500

0.14

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

$ 206.754

Ausgegebene Aktien

108.887.215

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

-8,71

Gewinn pro Aktie (EPS)

-0,02

Erlöse (LTM)

889,57k

Nettogewinn (LTM)

-1,63M

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headqu... Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. Mehr anzeigen

Sektor

Healthcare

Branche

Biotechnology & Life Sciences

Website

pharmala.ca

Hauptsitz

Vancouver, Canada

Gegründet

Pharmala Biotech Holdings Inc is listed in the Healthcare sector of the Canadian Securities Exchange with ticker MDMA. The last closing price for Pharmala Biotech was $0,14. Over the last year, Pharmala Biotech shares have traded in a share price range of $ 0,085 to $ 0,195.

Pharmala Biotech currently has 108.887.215 shares in issue. The market capitalisation of Pharmala Biotech is $15,24 million. Pharmala Biotech has a price to earnings ratio (PE ratio) of -8.71.

Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a...

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF...

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President...

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF...

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

PharmAla Issues Q2 Financial Statements and Grants Options

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”...

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

Cortexa Advances Commercialisation of MDMA Supply in Australia

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading...

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.005	-3.44827586207	0.145	0.145	0.13	58819	0.13859256	CS
4	-0.03	-17.6470588235	0.17	0.175	0.13	96964	0.14842653	CS
12	0.03	27.2727272727	0.11	0.195	0.085	223549	0.15880015	CS
26	0.035	33.3333333333	0.105	0.195	0.085	160122	0.14026853	CS
52	0.045	47.3684210526	0.095	0.195	0.085	172947	0.128368	CS
156	-0.225	-61.6438356164	0.365	0.425	0.065	318482	0.18559325	CS
260	-0.3	-68.1818181818	0.44	0.54	0.02	438438	0.18482588	CS

MDMA - Frequently Asked Questions (FAQ)

What is the current Pharmala Biotech Holdings Inc share price?

The current share price of Pharmala Biotech Holdings Inc is $ 0,14

How many Pharmala Biotech Holdings Inc shares are in issue?

Pharmala Biotech Holdings Inc has 108.887.215 shares in issue

What is the market cap of Pharmala Biotech Holdings Inc?

The market capitalisation of Pharmala Biotech Holdings Inc is CAD 15,24M

What is the 1 year trading range for Pharmala Biotech Holdings Inc share price?

Pharmala Biotech Holdings Inc has traded in the range of $ 0,085 to $ 0,195 during the past year

What is the PE ratio of Pharmala Biotech Holdings Inc?

The price to earnings ratio of Pharmala Biotech Holdings Inc is -8,71

What is the cash to sales ratio of Pharmala Biotech Holdings Inc?

The cash to sales ratio of Pharmala Biotech Holdings Inc is 16,52

What is the registered address of Pharmala Biotech Holdings Inc?

The registered address for Pharmala Biotech Holdings Inc is 1055 West Georgia Street, Vancouver, British Columbia, V6E 4N7

What is the Pharmala Biotech Holdings Inc website address?

The website address for Pharmala Biotech Holdings Inc is pharmala.ca

Which industry sector does Pharmala Biotech Holdings Inc operate in?

Pharmala Biotech Holdings Inc operates in the Biotechnology & Life Sciences sector

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Pharmala Biotech Holdings Inc (MDMA)

Pharmala Biotech Holdings Inc (MDMA) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Pharmala Biotech Holdings Inc

MDMA Neueste Nachrichten

Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

Cortexa Advances Commercialisation of MDMA Supply in Australia

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

Cortexa Advances Commercialisation of MDMA Supply in Australia

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

MDMA - Frequently Asked Questions (FAQ)

MDMA Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen